ART-TG and VRI teams have received 3-year funding from ANRS to develop new HIV vaccines based on CRISPR genome editing of B cells.
ART-TG
HIV B-VAC project funded by ANRS
Updated: May 10, 2021
top of page
bottom of page
Updated: May 10, 2021
ART-TG and VRI teams have received 3-year funding from ANRS to develop new HIV vaccines based on CRISPR genome editing of B cells.
Comments